- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | CHOSA ONCOLOGY AB: CHOSA Oncology accelerates value creation by entering into a commercially driven licensing agreement with Aida Oncology | 2 | Cision News | ||
| 15.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the result of exercise of warrants TO2 | 1 | Cision News | ||
| 13.07. | CHOSA ONCOLOGY AB: Members of executive management participate in the ongoing warrant - exercise ending tomorrow | 1 | Cision News | ||
| 10.07. | CHOSA ONCOLOGY AB: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP | 1 | Cision News | ||
| 07.07. | Spotlight Stock Market: Market Notice 76/26 - Last day of trading in CHOSA Oncology AB's subscription option CHOSA TO 2 | 1 | Cision News | ||
| 01.07. | CHOSA ONCOLOGY AB: CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78 | 2 | Cision News | ||
| 23.06. | CHOSA ONCOLOGY AB: CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP | 1 | Cision News | ||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study | 1 | Cision News | ||
| CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers | 4 | Cision News | ||
| 27.05. | Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB | 1 | Cision News | ||
| 06.05. | CHOSA ONCOLOGY AB: CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025 | 1 | Cision News | ||
| 27.04. | CHOSA ONCOLOGY AB: CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer | 2 | Cision News | ||
| 24.04. | Notice of annual general meeting in Chosa Oncology AB | 1 | Cision News | ||
| 24.04. | CHOSA ONCOLOGY AB: CHOSA to present new Platin-DRP data at ASCO 2026 | 1 | Cision News | ||
| 26.03. | CHOSA ONCOLOGY AB: CHOSA presents positive data on Platin-DRP predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026 | 1 | Cision News | ||
| 19.03. | CHOSA ONCOLOGY AB: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress | 1 | Cision News |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,050 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,360 | -2,75 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,060 | -5,89 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -3,36 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 118,49 | +2,65 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| BEAM THERAPEUTICS | 24,200 | -3,87 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,050 | +2,04 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| COGENT BIOSCIENCES | 33,650 | -1,46 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,540 | -0,71 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| TYRA BIOSCIENCES | 23,550 | +7,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ALUMIS | 9,910 | +1,12 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| IMMUNOVANT | 37,790 | -2,48 % | Immunovant, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 339,14 | -1,78 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TARSUS PHARMACEUTICALS | 81,55 | -1,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen |
Das Unternehmen CHOSA ONCOLOGY AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,047 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHOSA ONCOLOGY AB finden Sie auf Wallstreet Online.